Michael H. Davidson to Diabetes Mellitus, Type 2
This is a "connection" page, showing publications Michael H. Davidson has written about Diabetes Mellitus, Type 2.
Connection Strength
2.498
-
Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus. Postgrad Med. 2014 May; 126(3):56-65.
Score: 0.247
-
Cardio-diabetes: special considerations for the patient with diabetes and cardiovascular disease. Introduction. Am J Cardiol. 2012 Nov 06; 110(9 Suppl):1B-3B.
Score: 0.223
-
Pioglitazone versus glimepiride on coronary artery calcium progression in patients with type 2 diabetes mellitus: a secondary end point of the CHICAGO study. Arterioscler Thromb Vasc Biol. 2010 Sep; 30(9):1873-6.
Score: 0.189
-
The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus. Trends Cardiovasc Med. 2009 Apr; 19(3):94-9.
Score: 0.174
-
A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome. Am J Cardiol. 2008 Dec 22; 102(12A):19L-27L.
Score: 0.170
-
Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin-converting enzyme inhibitors. Endocr Pract. 2008 Nov; 14(8):985-92.
Score: 0.169
-
Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. Circulation. 2008 Apr 22; 117(16):2123-30.
Score: 0.162
-
Global risk management in patients with type 2 diabetes mellitus. Am J Cardiol. 2007 Feb 19; 99(4A):41B-50B.
Score: 0.148
-
Plasminogen activator inhibitor-1 and the risk of Type 2 diabetes mellitus in American Indians: the Strong Heart Study. Diabet Med. 2006 Oct; 23(10):1158-9.
Score: 0.146
-
Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions. Expert Opin Drug Saf. 2006 Jan; 5(1):145-56.
Score: 0.139
-
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. Endocr Pract. 2017 Apr; 23(Suppl 2):1-87.
Score: 0.076
-
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2015 EXECUTIVE SUMMARY. Endocr Pract. 2015 Dec; 21(12):1403-14.
Score: 0.069
-
AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013 Mar-Apr; 19(2):327-36.
Score: 0.057
-
Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk. Diabetes Obes Metab. 2012 Jan; 14(1):30-9.
Score: 0.052
-
Pioglitazone-mediated changes in lipoprotein particle composition are predicted by changes in adiponectin level in type 2 diabetes. J Clin Endocrinol Metab. 2012 Jan; 97(1):E110-4.
Score: 0.052
-
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. Am J Cardiovasc Drugs. 2010; 10(2):73-84.
Score: 0.046
-
Hypertriglyceridemic waist phenotype predicts increased visceral fat in subjects with type 2 diabetes. Diabetes Care. 2009 Oct; 32(10):1916-20.
Score: 0.044
-
Relation of abdominal fat depots to systemic markers of inflammation in type 2 diabetes. Diabetes Care. 2009 May; 32(5):932-7.
Score: 0.043
-
Relationship of abdominal visceral and subcutaneous adipose tissue with lipoprotein particle number and size in type 2 diabetes. Diabetes. 2008 Aug; 57(8):2022-7.
Score: 0.041
-
Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008 Apr; 31(4):811-22.
Score: 0.040
-
Type 2 diabetes and cardiovascular disease: reducing the risk. J Manag Care Pharm. 2007 Mar; 13(2 Suppl A):S2-15; quiz S16-7.
Score: 0.038
-
Reducing the risk of stroke through appropriate targets and treatments. Prev Cardiol. 2007; 10(4):215-21.
Score: 0.037
-
Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA. 2006 Dec 06; 296(21):2572-81.
Score: 0.037
-
Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology. J Gerontol A Biol Sci Med Sci. 2005 Apr; 60(4):471-5.
Score: 0.033
-
Sucrose-induced cardiomyocyte dysfunction is both preventable and reversible with clinically relevant treatments. Am J Physiol Endocrinol Metab. 2004 May; 286(5):E718-24.
Score: 0.031
-
Fiber intake and risk of developing non-insulin-dependent diabetes mellitus. JAMA. 1997 Jun 11; 277(22):1761; author reply 1762.
Score: 0.019
-
Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk. Atherosclerosis. 2010 Nov; 213(1):1-7.
Score: 0.012
-
Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia. Am J Cardiol. 2000 Aug 15; 86(4):406-11.
Score: 0.006